Search Results
Apr 16, 2026, 09:17 ET ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
Apr 16, 2026, 00:01 ET U.S. News & World Report Launches 2026 Banking and Investing Platform Awards
Sallie Mae's 60-Month CD account secured the award for Editors' Choice: Best to Lock in High Rates. The financial institution secured its high honor from U.S. News due to competitive interest rates and a low minimum requirement to open and maintain a CD account.For investors interested
More news about: U.S. News & World Report, L.P.
Apr 15, 2026, 23:32 ET Global First | NMPA Accepts IND Application for Mabwell's Innovative LILRB4/CD3 TCE Bispecific Antibody 6MW5311
targets LILRB4 and CD3, forming an immunological synapse by bridging tumor cells and T cells, thereby activating T cells to efficiently kill tumors.The molecule incorporates a unique steric hindrance design. This structure significantly reduces the binding activity of the CD3 antibody to T cells
More news about: Mabwell
Apr 15, 2026, 23:00 ET 全球首款 | 邁威生物靶向 LILRB4/CD3 TCE 雙抗創新藥 6MW5311 臨床試驗申請獲 NMPA 受理
2026年4月16日 /美通社/ -- 邁威生物 (688062.SH)，一家全產業鏈佈局的創新型生物製藥公司，宣佈國家藥品監督管理局（NMPA）已受理其靶向 LILRB4/CD3 TCE 雙抗創新藥（研發代號：6MW5311）的臨床試驗申請，擬開發適應症為血液瘤（急性髓系白血病、慢性粒單核細胞白血病以及多發性骨髓瘤）。6MW5311 為全球首款申報臨床的靶向 LILRB4/CD3 TCE 雙抗創新藥，具備廣闊的臨床開發前景和市場潛力，其美國臨床試驗申請目前處於 pre IND 階段，計劃於 2026 年第二季度向 FDA 正式遞交申請。 6MW5311 基於
More news about: 邁威生物
Apr 15, 2026, 12:03 ET Adimab Collaborator GSK Receives Additional Marketing Approval for Depemokimab
cells (mice, llamas, and humans), antibody engineering and optimization, bi- and multispecific antibody engineering, and a portfolio of proprietary CD3 and CD28 antibodies with complementary heterodimerization mutations that are licensed non-exclusively for bi- and multispecific applications. Adimab focuses
More news about: Adimab, LLC
Apr 15, 2026, 09:00 ET Gitar Launches from Stealth with $9M as AI-Generated Code Outpaces Teams' Ability to Validate and Ship Software Safely
experience in developer infrastructure, most recently serving as a Principal Engineer on Uber's Developer Platform team. His expertise spans build systems, CI/CD, and IDE tooling, and he has contributed to open source projects adopted by leading engineering organizations including Square, Airbnb, and Lyft.That
More news about: Gitar
Apr 15, 2026, 08:00 ET Verismo Therapeutics Announces $28 Million Investment from HLB Innovation to Accelerate KIR-CAR Clinical Development
Novel SynKIR™-310 outperforms CD3-based second-generation CD28 or 41BB co-stimulated CAR T in B cell non-Hodgkin lymphoma xenograft mice and shows early clinical signalLate-Breaking
More news about: Verismo Therapeutics
Apr 15, 2026, 01:01 ET Ailoitte Bets Big on AI-First Engineering: Introduces AI Velocity Pods for 3x Faster Product Delivery
the job. Every Pod is led by engineers with deep domain expertise.Autonomous AI Agents that handle code generation, automated testing, CI/CD pipeline management, documentation, code review, and boilerplate production - tasks that consume 30-60% of a traditional developer's day according
More news about: Ailoitte
Apr 14, 2026, 12:48 ET FHN Financial Expands Brokered CD Capabilities with New Underwriting and Trading Desk
Senior Vice Presidents of CD Underwriting and Trading. Together, they have executed billions of dollars in CD transactions over the past 20 years and have extensive experience building and leading CD underwriting, trading and brokered funding platforms."The brokered CD market plays a vital role
More news about: FHN Financial
Apr 13, 2026, 15:00 ET BioOra and Cincinnati Children's Hospital Medical Center Partner to Advance Next-Generation CAR-T Therapy for Children with Leukaemia
and Cincinnati Children's today announced a strategic partnership to advance Atla-cel, (atlacabtagene autoleucel, pINN List 134), a third-generation CD19-directed CAR-T cell therapy, into clinical development for children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukaemia
More news about: BioOra
Apr 13, 2026, 08:44 ET Banistmo Announces Launch of Consent Solicitation for 4.250% Senior Notes due 2027
06034L AB6P15383 CD5U.S.$391,961,000
More news about: Banistmo, S.A.
Apr 10, 2026, 09:39 ET ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP
Apr 09, 2026, 20:00 ET Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
engineering and CD3 masking, IBI3055 is designed to achieve this balance and provide a safer and more effective treatment option for patients."About IBI3055 (CD19/BCMA/CD3 Tri-specific Antibody)IBI3055 is an internally developed tri-specific antibody targeting CD19, BCMA, and CD3, featuring
More news about: Innovent Biologics
Apr 09, 2026, 08:47 ET Inflectra Launches Free Early Access for SureWire™: The First Specialized QA Platform Built to Stress-Test AI Agents
Testing and Judge Agents during the beta period.Roadmap Influence: A direct line to the Inflectra team to shape future features like CI/CD integration and audit-ready reports.Locked-in early adopter rates: Early Access members receive preferred pricing when SureWire reaches
More news about: Inflectra Corporation
Apr 09, 2026, 08:36 ET Sealed Air Announces Completion of Acquisition by CD&R
Lazard, Mizuho, RBC Capital Markets, UBS Investment Bank and Wells Fargo served as financial advisors to CD&R. Kirkland & Ellis LLP and Debevoise & Plimpton LLP served as legal counsel to CD&R.About Sealed AirSealed Air Corporation is a leading global provider of packaging
More news about: Sealed Air
Apr 09, 2026, 08:00 ET Appknox Launches KnoxIQ, an AI Co-Pilot to Prioritize Real-World Exploitability in Application Security
2000 companies and government organizations across 60+ countries, Appknox specializes in detecting AI vulnerabilities and seamlessly integrates with CI/CD pipelines. Our enterprise-grade solutions help financial services, healthcare, and retail organizations meet global compliance requirements while protecting
More news about: Appknox
Apr 09, 2026, 08:00 ET Invicti Launches DAST-to-SAST Correlation to Help DevOps Fix Verified Runtime Risks at Pipeline Speed
and distributed API-based architectures, Invicti's DAST-to-SAST correlation empowers DevSecOps teams to find and fix vulnerabilities earlier in the CI/CD pipeline, where remediation is faster, cheaper, and less disruptive, reducing risk exposure and enabling more confident release decisions.AvailabilityDAST-to-SAST
More news about: Invicti Security
Apr 08, 2026, 16:51 ET Gartner prevê que, até 2028, Inteligência Artificial Explicável impulsionará investimentos em observabilidade de LLM para 50% das implementações de GenAI
contínua de LLM em pipelines de integração contínua (CI) / entrega contínua (CD): Integrar métricas de avaliação de LLM, incluindo benchmarks de precisão factual e verificações de segurança, em pipelines de CI / CD para validação contínua antes da implementação. - Capacitação de
More news about: Gartner
Apr 08, 2026, 08:00 ET Oglethorpe Power Fourth Quarter and Year-End 2025 Investor Briefing Call to Be Held April 14
https://register-conf.media-server.com/register/BI069cd65ab617401490aaf663bc0069b7Participants who join by telephone can ask questions at the end of the call.Shortly following
More news about: Oglethorpe Power Corporation
Apr 07, 2026, 15:05 ET Phanes Therapeutics announces dose expansion in clinical study of spevatamig in combination with chemotherapy for treatment of biliary tract cancer
Spevatamig is a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47. It was granted orphan drug designation (ODD) for the treatment of pancreatic cancer by the FDA in 2022 and was granted Fast Track designation for the
More news about: Phanes Therapeutics
Apr 07, 2026, 10:45 ET Platformr Launches an AWS Security Assessment Report in partnership with the AWS Security Health Improvement Program
results in six hours: a multi-account AWS landing zone, deployment of 45+ foundational AWS services, real-time compliance monitoring, and automated CI/CD pipelines – all while reducing monthly cloud costs by 56%.Getting StartedAWS customers can request a free Platformr security assessment
More news about: Platformr
Apr 07, 2026, 09:00 ET April 2026 CD Rate Trends: CD Valet Finds Slowing Pace of CD Rate Cuts as Market Uncertainty Grows
uncertainty."About CD ValetCD Valet is a CD marketplace that features verified CD rates from federally insured banks and credit unions. With tens of thousands of CD offers tracked across the country, CD Valet gives savers a clear view of top rates and helps them explore high-yield CD options with
More news about: CD Valet
Apr 07, 2026, 09:00 ET DBmaestro Introduces Agentic Database DevOps with MCP Server
DBmaestro MCP server exposes the company's industry-leading database release automation, source control, CI/CD orchestration, and compliance capabilities to AI agents and enterprise copilots. Teams can now use natural language to trigger real DBmaestro workflows
More news about: DBmaestro
Apr 07, 2026, 07:45 ET TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations
Before that, Mrs. Garofolo directed the submission of 3 new IND submissions in just 12 months, resulting in the successful commencement of the anti-TIGIT, CD-73 inhibitor, and A2a/A2b adenosine receptor antagonist programs at Arcus Biosciences. Mrs. Garofalo has also served as the Global Clinical Program Lead
More news about: TuHURA Biosciences, Inc.
Apr 03, 2026, 08:59 ET ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Faruqi & Faruqi, LLP